Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 55 for “"FSHD"”.
-
Growing up with FSHD. Characteristics of early-onset FSHD and childhood FSHD
Radboud University, 02 april 2020
-
Mechanisms of toxicity in cell models of FSHD
… for facioscapulohumeral muscular dystrophy (FSHD). Whereas DUX4 expression normally occurs during early embryonic development, ectopic DUX4 expression is highly toxic in human cells. In my thesis work, using a new cell model with regulated expression of DUX4, I found that expression of DUX4 …
-
Morphologische Untersuchungen an Myoblasten von Patienten, die an facioscapulohumeraler Muskeldystrophie (FSHD) leiden
… vererbte facioscapulohumerale Muskeldystrophie (FSHD) ist mit einer Prävalenz von etwa 1:20.000 die dritthäufigste Form der hereditären Myopathien. Erste Beschwerden werden meist in der zweiten Lebensdekade beobachtet. Betroffen sind vor allem die Muskulatur von Gesicht, Schultern, Oberarmen, die …
-
Zur genetischen Heterogenität der Muskeldystrophien: alternative genetische Ursachen der Myotonen Dystrophie und FSHD
… (DM) und Facioscapulohumerale Muskeldystrophie (FSHD), bei denen alternative genetische Ursachen, sowie anknüpfende Fragestellungen untersucht wurden. Das erste Projekt dieser Arbeit beschäftigt sich mit Fragestellungen, welche die DM betreffen. Die DM Typ 1 und Typ 2 (DM1 und DM2) bilden …
-
DUX4 expression in development versus disease: DUX4 expression in spermatogenesis, placentation, cancer and FSHD
… causative gene of facioscapulohumeral dystrophy (FSHD). Recently, DUX4 has been credited for driving the totipotent program in naïve embryonic stem cells, and for driving immune evasive properties in an assortment of cancers. Thus, DUX4 has its fingers in a lot of pots, but its mode of expression …
-
The First Steps in the New Era of FSHD Trials - Trial Readiness, Execution and Evaluation
… not ideal as outcome measures for drug trials in FSHD. We also tested a drug called losmapimod for safety and effectiveness. This study showed that it was safe and may have shown an inhibitory effect on the disease. A later study showed that the drug was ineffective (not in this thesis). Muscle …
-
Development of an Allele-Aware Method to Study the Nuclear Organization of the FSHD Locus
… at this locus lead to the muscular dystrophy FSHD through an epigenetic mechanism that results in inappropriate expression of DUX4, a transcription factor encoded in each repeat unit that is normally active in the germline. DUX4 is toxic to muscle cells, yet its high abundance in only a small …
-
LINEE CELLULARI DERIVATE DA PAZIENTI AFFETTI DA DISTROFIA FACIO-SCAPOLO-OMERALE (FSHD) DI TIPO 1 E 2 MOSTRANO LUNGO IL DIFFERENZIAMENTO MIOGENICO PROFILI DIVERSI DI ESPRESSIONE GENICA.
Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant disorder mainly associated with a contraction of the subtelomeric repeat D4Z4 on chromosome 4. The D4Z4 copy number is highly polymorphic in normal individuals ranging between 11-150 copies, whereas almost all FSHD patients …
-
Molecular analysis of the facioscapulohumeral muscular dystrophy (FSHD) associated DNA rearrangements in the South African population
Facioscapulohumeral muscular dystrophy (FSHD) is the third most common inherited disorder of muscle after Duchenne and Myotonic dystrophy, with a prevalence of at least 1 in 20,000. FSHD is characterised by progressive weakening and atrophy of the face, shoulder-girdle and upper arm, although other …
-
FSHD in focus - A five-year follow-up study on clinical outcome measures and muscle imaging
Facioscapulohumeral muscular dystrophy (FSHD) is an incurable hereditary muscle disease. People with FSHD experience slowly progressive muscle weakness. This increase in muscle weakness is difficult to measure in the consultation room, which makes it challenging to evaluate new treatments for FSHD. …
-
Altered FRG1 Levels During Xenopus Laevis Development Leads to Muscular and Vascular Phenotypes Supporting a Role for the Misregulation of FRG1 in FSHD
… for facioscapulohumeral muscular dystrophy (FSHD) results in an epigenetic misregulation of gene expression, which in turn is what ultimately leads to the disease pathology. FRG1 (FSHD region gene 1) is a leading candidate gene whose misexpression may lead to FSHD. As FSHD pathology is most …
-
Analysis of Ret and β-catenin: transcriptional targets of the facioscapulohumeral muscular dystrophy (FSHD) candidate gene DUX4
… Facioscapulohumeral muscular dystrophy (FSHD) is the third commonest muscular dystrophy, caused by contraction in the number of repeat units (D4Z4) on 4q35. A D4Z4 contraction on the chromosomal haplotype 4qA leads to the production of double homeobox protein (DUX4) in muscle cells. DUX4 …
-
Muscle stem cell function in facioscapulohumeral muscular dystrophy
Facioscapulohumeral muscular dystrophy (FSHD) is a prevalent, incurable myopathy with highly heterogenous clinical trajectories, in which abnormal expression of the transcription factor DUX4 results in progressive skeletal muscle atrophy. Mounting evidence suggests DUX4 expression in FSHD patients …
-
Anatomic, functional, and physiologic implications of altered body composition among people with Facioscapulohumeral muscular dystrophy
Facioscapulohumeral muscular dystrophy (FSHD) is a dominantly-inherited myopathy, with estimated prevalence rates ranging from 1:8,000-20,000. As with other autosomal dominant diseases, alterations in gene expression are theorized to be responsible for the pathologic changes associated with FSHD. …
-
Genetic and Epigenetic Regulation in the Facioscapulohumeral Muscular Dystrophy-associated Genome
Facioscapulohumeral muscular dystrophy (FSHD) is one of the most common muscular dystrophies. It initially causes progressive weakness and wasting of the face, shoulder and upper arm muscles, but eventually could also affect all the skeletal muscles. FSHD has a complex etiology characterized by …
-
RUOLO DEI MICRORNA NEL DIFFERENZIAMENTO MIOGENICO NORMALE E PATOLOGICO
riassunto Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant disease, is the third most common myopathy, with an incidence of 1 in 15.000 in the general population. Clinical symptoms appear during the second decade of age and are characterized by progressive muscle weakness and …
-
Exploring the role of inflammation in facioscapulohumeral muscular dystrophy
In the muscle disease FSHD, inflammation may play an important role. This research shows that certain inflammatory substances, like IL-6 and TNF, are elevated in FSHD patients and are linked to disease severity. Immune cells, such as Natural Killer (NK) cells, are also activated. While it was …
-
THERAPEUTIC DEVELOPMENT FOR FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY UTILIZING A NOVEL HUMAN SKELETAL MUSCLE XENOGRAFT MODEL
… such as facioscapulohumeral muscular dystrophy (FSHD) deprive patients of their physical strength and quality of life. Animal models have been indispensable in the research investigation and therapeutic development for genetic muscle disorders. But the successful leap from bench to bedside rarely …
-
Analysis of the translocation events between the repeat arrays from chromosomes 4q35 and 10q26 in the South Africa facioscapulohumeral muscular dystrophy (FSHD) population
Facioscapulohumeral muscular dystrophy (FSHD) is a progressive autosomal dominant myopathy, preferentially affecting facial, shoulder girdle and upper-arm muscles. It is one of the most common muscular dystrophies with a prevalence of 1 in 20,000. The rearrangement that results in FSHD entails a …
Page 1 of 3